In accordance with Section 29 of the Securities Trading Act, Novo Nordisk hereby reports that Capital Group Companies on 12 October 2007 informed Novo Nordisk that Capital Group Companies now holds 48,127,241 B shares of DKK 2 equal to 14.88% of the total share capital in Novo Nordisk.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
|
Media: |
Investors: |
|
Outside North America: |
Outside North America: |
|
Elin K Hansen |
Mads Veggerby Lausten |
|
Tel (direct): (+45) 4442 3450 |
Tel (direct): (+45) 4443 7919 |
|
|
|
|
|
Hans Rommer |
|
|
Tel (direct): (+45) 4442 4765 |
|
|
|
|
|
|
|
In North America: |
In North America: |
|
Sean Clements |
Christian Qvist Frandsen |
|
Tel (direct): (+1) 609 514 8316 |
Tel (direct): (+1) 609 919 7937 |
Stock Exchange Announcement no 28 / 2007